On January 10, 2025, the U.S. Food and Drug Administration (FDA) released released a long-term national strategy to increase the resilience of the U.S. infant formula market.

On January 10, FDA released its Long-Term National Strategy to Increase the Resilience of the U.S. Infant Formula Market, which builds on the Short-Term National Strategy to Increase the Resilience of the U.S. Infant Formula Market, and is a direct response to the February 2022 U.S. infant formula recall and subsequent supply shortages. The Long-Term Strategy identifies actions taken by FDA since 2023 and focuses on the long-term goal of achieving a stronger, more resilient U.S. infant formula supply.

Long-term actions to improve information sharing across all stakeholder groups are outlined in the long-term strategy, as well as actions taken since 2023 to help protect the integrity of the infant formula supply chain. The long-term strategy also addresses the implementation of measures to prevent contamination, incentivize new infant formula manufacturers to enter the U.S. market, and the need for authorities to better understand the supply chain and the risk of shortages.FDA is committed to working with all stakeholders to increase the resilience of the infant formula supply and ensure that consumers have confidence that infant formula available in the U.S. market is safe and nutritious.

Learn more: